Please provide your email address to receive an email when new articles are posted on . Relfydess has received a positive decision for treatment of frown lines and crow’s feet in the European Union.
First results from the phase IIIb RELAX clinical trial reinforce the high and sustained efficacy of single treatment of RelabotulinumtoxinA (Relfydess TM) for moderate to severe frown lines (glabellar ...
(MENAFN- EIN Presswire) EINPresswire/ -- Face Value Cosmetic Medicine Clinic in Christchurch has begun offering Relfydess, a new anti-wrinkle injectable treatment designed to deliver faster onset and ...
ZUG, Switzerland — Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American ...
(BUSINESS WIRE )--Galderma will present the latest updates from its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2025 on January 30 – ...
At ASDS 2025, Galderma unveiled pivotal new data from its range of pioneering Restylane ® hyaluronic acid (HA) injectables, highlighting its versatility in improving the chin profile with Restylane ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results